TNYAbenzinga

Tenaya Therapeutics Announces Progress In Gene Therapies TN-201 And TN-401 For Cardiomyopathies; Dosing Started In Cohort 2 Of MyPEAK-1 Phase 1b/2 Trial; Cohort 1 Data Expected H1 2025; Initial Data From RIDGE-1 Trial Of TN-401 Expected In H2 2025

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 13, 2025 by benzinga